Erratum: Optimal attenuation of experimental autoimmune encephalomyelitis by intravenous immunoglobulin requires an intact interleukin-11 receptor (PLoS ONE (2014) 9:7 (e101947) DOI 10.1371/journal.pone.0101947);Optimal attenuation of experimental autoimmune encephalomyelitis by intravenous immunoglobulin requires an intact interleukin-11 receptor

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Figueiredo, Carlyn A ^a,b   Drohomyrecky, Paulina C ^d   McCarthy, Stephen D S ^a,b   Leontyev, Danila ^a   Ma, Xue Zhong ^a   Branch, Donald R ^a,b,c   Dunn, Shannon E ^c,d,e  

^a CANADIAN BLOOD SERVICES   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMUNEX; IMMUNOGLOBULIN G; INTERLEUKIN 11; INTERLEUKIN 11 RECEPTOR ALPHA; MESSENGER RNA; MYELIN; PRIVAGEN; UNCLASSIFIED DRUG; IMMUNOGLOBULIN; INTERLEUKIN 11 RECEPTOR; INTERLEUKIN 17;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEMYELINATION; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GENE EXPRESSION REGULATION; IL 11 GENE; INCIDENCE; LYMPHOCYTE PROLIFERATION; MONONUCLEAR CELL; MOUSE; NEUROPROTECTION; NONHUMAN; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL; TREATMENT RESPONSE; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; METABOLISM; PHYSIOLOGY; T LYMPHOCYTE;

ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; IMMUNOGLOBULINS, INTRAVENOUS; INTERLEUKIN-11; INTERLEUKIN-17; MICE; RECEPTORS, INTERLEUKIN-11; T-LYMPHOCYTES;

EID: 84905404133     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113001     Document Type: Erratum

References (57)

1. Schwab I, Nimmerjahn F (2013) Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 13: 176-189.
2. Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, et al. (1981) High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1: 1228-1231.
3. Berkman SA, Lee ML, Gale RP (1988) Clinical uses of intravenous immunoglobulins. Seminars in hematology. Semin Hematol 25: 140-158.
4. Schwartz SA (1990) Intravenous immunoglobulin (IVIG) for the therapy of autoimmune disorders. J Clin Immunol 10: 81-89.
5. Chipps E, Skinner C (1994) Intravenous immunoglobulin: implications for use in the neurological patient. J Neurosci Nurs 26: 8-17.
6. Gelfand EW (2012) Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 367: 2015-2025.
7. Ratko TA, Burnett DA, Foulke GE, Matuszewski KA, Sacher RA (1995) Recommendations for off-label use of intravenously administered immunoglobulin preparations. University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations. JAMA 273: 1865-1870.
8. Foster R, Suri A, Filate W, Hallett D, Meyer J, et al. (2010) Use of intravenous immunoglobulin in the ICU: a retrospective review of prescribing practices and patient outcomes. Transfusion Med 20: 403-408.
9. Katz U, Shoenfeld Y, Zandman-Goddard G (2011) Update on intravenous immunoglobulins (IVIg) mechanisms of action and off- label use in autoimmune diseases. Curr Pharm Des 17: 3166-3175.
10. Branch DR (2013) Unraveling the IVIG mystique. Transfusion 53: 242-244.
11. Crow AR, Song S, Freedman J, Helgason CD, Humphries RK, et al. (2003) IVIg-mediated amelioration of murine ITP via FcgammaRIIB is independent of SHIP1, SHP-1, and Btk activity. Blood 102: 558-560. (Pubitemid 36841975)
12. Ichiyama T, Ueno Y, Hasegawa M, Ishikawa Y, Matsubara T, et al. (2005) Intravenous immunoglobulin does not increase FcgammaRIIB expression on monocytes/macrophages during acute Kawasaki disease. Rheumatology (Oxford) 44: 314-317. (Pubitemid 40361286)
13. Leontyev D, Katsman Y, Branch DR (2012) Mouse background and IVIG dosage are critical in establishing the role of inhibitory Fc c receptor for the amelioration of experimental ITP. Blood 119: 5261-5264.
14. Othy S, Hegde P, Topçu S, Sharma M, Maddur MS, et al. (2013) Intravenous gammaglobulin inhibits encephalitogenic potential of pathogenic T cells and interferes with their trafficking to the central nervous system, implicating sphingosine-1 phosphate receptor 1-mammalian target of rapamycin axis. J Immunol 190: 4535-4541.
15. Guhr T, Bloem J, Derksen NI, Wuhrer M, Koenderman AH, et al. (2011) Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia. PLoS One 6: e21246.
16. Leontyev D, Katsman Y, Ma XZ, Miescher S, Käsermann F, et al. (2012) Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin. Transfusion 52: 1799-1805.
17. Keegan BM, Noseworthy JH. (2004) Multiple Sclerosis. Annu Rev Med 53: 285-302.
18. Curtin F, Hartung HP (2014) Novel therapeutic options for multiple sclerosis. Expert Rev. Clin. Pharmacol. 7: 91-104.
19. Cohen JA (2008) How effective is intravenous immunoglobulin for the treatment of relapsing-remitting multiple sclerosis? Nat Clin Prac Neurol 4: 588-589.
20. Dudesek A, Zetti UK (2006) Intravenous immunoglobulins as therapeutic option in the treatment of multiple sclerosis. J Neurol 253: V50-V58.
21. Durandy A, Kaveri SV, Kuijpers TW, Basta M, Miescher S, et al. (2009) Intravenous immunoglobulins-understanding properties and mechanisms. Clin Exp Immunol 158: 2-13.
22. Sørensen PS (1994) Treatment of multiple sclerosis with IVIg: potential effects and methodology of clinical trials. J Neurol Neurosurg Psychiatry 57 Suppl: 62-64.
23. Pashov A, Bellon B, Kaveri SV, Kazatchkine MD (1997) A shift in encephalitogenic T cell cytokine pattern is associated with suppression of EAE by intravenous immunoglobulins (IVIg). Mult Scler 3: 153-156. (Pubitemid 27390392)
24. + regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 111: 715-722.
25. Pigard N, Elovaara I, Kuusisto H, Paalavuo R, Daastidar P, et al. (2009) Therapeutic activities of intravenous immunoglobulins in multiple sclerosis involve modulation of chemokine expression. J Neuroimmunol 209: 114-120.
26. Leng SX, Elias JA (1997) Interleukin-11. Int J Biochem Cell Biol 29: 1059-1062. (Pubitemid 27511716)
27. Nishina T, Komazawa-Sakon S, Yanaka S, Piao X, Zheng DM, et al. (2012) Interleukin-11 links oxidative stress and compensatory proliferation. Sci Signal 5: ra5.
28. Gurfein BT, Zhang Y, López CB, Argaw AT, Zameer A, et al. (2009) IL-11 regulates autoimmune demyelination. J Immunol 183: 4229-4240.
29. Dunn SE, Bhat R, Straus DS, Sobel RA, Axtell R, et al. (2010) Peroxisome proliferator-activated receptor delta limits the expansion of pathogenic Th cells during central nervous system autoimmunity. J Exp Med 207: 1599-1608.
30. Ramakrishna C, Newo AN, Shen YW, Cantin E (2011) Passively administered pooled human immunoglobulins exert IL-10 dependent anti-inflammatory effects that protect against fatal HSV encephalitis. PLoS Pathog: 7: e1002071.
31. Kessel A, Ammuri H, Peri R, Pavlotzky ER, Blank M, Shoenfeld Y, et al. (2007) Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol 179: 5571-5575.
32. + regulatory T cells conveying respiratory tolerance. J Immunol 189: 1975-1982.
33. Redpath SA, van der Werf N, Cervera AM, MacDonald AS, Gray D, Maizels RM, et al. (2013) ICOS controls Foxp3(+) regulatory T-cell expansion, maintenance and IL-10 production during helminth infection. Eur J Immunol 43: 705-715.
34. Humle Jorgensen S, Sorensen PS (2005) Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. J Neurol Sci 233: 61-65.
35. Jorgensen SH, Jensen PE, Laursen H, Sorensen PS (2005) Intravenous immunoglobulin ameliorates experimental autoimmune encephalomyelitis and reduces neuropathological abnormalities when administered prophylactically. Neurol Res 27: 591-597. (Pubitemid 41232629)
36. + T regulatory cells is associated with their peripheral deficiency and thrombocytopenia in a murine model of thrombocytopenia. Blood 120: 2127-2132.
37. Maddur MS, Vani J, Hegde P, Lacroix-Desmazes S, Kaveri SV, et al. (2011) Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin. J Allergy Clin Immunol 127: 823-830.
38. + regulatory T cells is associated with resistance to intravenous immunoglobulin therapy in patients with Kawasaki disease. Eur J Pediatr 172: 833-837.
39. Tjon AS, Tha-In T, Metselaar HJ, van Gent R, van der Laan LJ, et al. (2013) Patients treated with high-dose intravenous immunoglobulin show selective activation of regulatory T cells. Clin Exp Immunol 173: 259-267.
40. Chi LJ, Wang HB, Zhang Y, Wang WZ (2007) Abnormality of circulating CD4(+) CD25(+) regulatory T cell in patients with Guillain-Barre syndrome. J Neuroimmunol 192: 206-214. (Pubitemid 350213129)
41. Masubuchi Y, Bourdi M, Reilly TP, Graf MLM, George JW, et al. (2003) Role of interleukin-6 in hepatic heat shock protein expression and protection against acetaminophen-induced liver disease. Biochem Biophys Res Commun 304: 207-212. (Pubitemid 36434217)
42. Bozza M, Bloss JL, Maylor R, Erickson J, Donnelly L, et al. (1999) Interleukin-11 reduces T cell dependent experimental liver injury in mice. Hepatology 30: 1441-1447.
43. Trepicchio WL, Bozza M, Bouchard P, Dorner AJ (2001) Protective effect of rhIL-11 in a murine model of acetaminophen-induced hepatotoxicity. Toxicol Pathol 29: 242-249. (Pubitemid 32531625)
44. Maeshima K, Takahashi T, Nakahira K, Shimizu H, Fujii H, et al. (2004) A protective role of interleukin 11 on hepatic injury in acute endotoxemia. Shock 21: 134-138.
45. Antonelli A, Neri S, Gasperini L, Alberti B, Saracino A, et al. (1992) Liver function tests, hepatitis A, B, and C markers and HIV antibodies in patients with Basdow's ophthalmopathy treated with intravenous immunoglobulins. Clin Ther 141: 55-61.
46. Oomes PG, van er Meche FG, Kleyweg RP (1996) Liver function disturbances in Guillain-Barre syndrome: a prospective longitudinal study in 100 patients. Neurology 46: 96-100.
47. Huang DR, Wang J, Kivisakk P, Rollins BJ, Ransohoff RM (2001) Absence ofmonocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 response in experimental autoimmune encephalomyelitis. J Exp Med 193: 713-726.
48. Ajami B, Bennett JL, Krieger C, McNagny KM, Rossi FM (2011) Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat Neurosci 14: 1142-1149.
49. Tran EH, Prince EN, Owens T (2002) IFN-gamma shapes immune invasion of the central nervous system via regulation of chemokines. J Immunol 164: 2759-2768. (Pubitemid 30115510)
50. O'Connor RA, Prendergast CT, Sabatos CA, Lau CW, Leech MD, et al. (2008) Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis. J Immunol 181: 3750-3754.
51. Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, et al. (2009) Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139: 485-498.
52. Zhang MA, Rego D, Moshkova M, Kebir H, Chruscinski A, et al. (2012) Peroxisome proliferator-activated receptor (PPAR)alpha and -gamma regulate IFNgamma and IL-17A production by human T cells in a sex-specific way. Proc Natl Acad Sci 109: 9505-9510.
53. Fedele G, Bianco M, Debrie AS, Locht C, Ausiello CM (2011) Attenuated Bordetella pertussis vaccine candidate BPZE1 promotes human dendritic cell CCL21-induced migration and drives a Th1/Th17 response. J Immunol 186: 5388-5396.
54. Watkatsuki A, Borrow P, Rigley K, Beverley PC (2003) Cell-surface bound pertussis toxin induces polyclonal T cell responses with high levels of interferon-gamma in the absence of interleukin-12. Eur J Immunol 33: 1859-1868. (Pubitemid 37120857)
55. Kerfoot SM, Long EM, Hickey MJ, Andonegui G, Lapointe BM, et al. (2004) TLR contributes to disease-inducing mechanisms resulting in central nervous system autoimmune disease. J Immunol 173: 7070-7077. (Pubitemid 39541097)
56. Zhang Y, Taveggia C, Melendez-Vasquez C, Einheber S, Raine CS, et al. (2006) Interleukin-11 potentiates oligodendrocyte survival and maturation, and myelin formation. J Neurosci 26: 12174-12185. (Pubitemid 44808384)
57. Maheshwari A, Janssens K, Bogie J, Van Den Haute C, Struys T, et al. (2013) Local overexpression of interleukin-11 in the central nervous system limits demyelination and enhances remyelination. Mediators Inflamm 2013: 685317.